S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
S&P 500   3,901.36
DOW   31,261.90
QQQ   288.68
NASDAQ:HSIC

Henry Schein (HSIC) Stock Forecast, Price & News

$83.45
+0.58 (+0.70%)
(As of 05/20/2022 06:55 PM ET)
Add
Compare
Today's Range
$81.76
$83.90
50-Day Range
$80.45
$91.96
52-Week Range
$70.25
$92.68
Volume
780,700 shs
Average Volume
995,006 shs
Market Capitalization
$11.52 billion
P/E Ratio
18.14
Dividend Yield
N/A
Beta
0.75
30 days | 90 days | 365 days | Advanced Chart
Receive HSIC News and Ratings via Email

Sign-up to receive the latest news and ratings for Henry Schein and its competitors with MarketBeat's FREE daily newsletter.

Henry Schein logo

About Henry Schein

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, personal protective equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners, and consulting and other services. Henry Schein, Inc. was founded in 1932 and is headquartered in Melville, New York.

Headlines

See More Headlines

Industry, Sector and Symbol

Industry
Medical & hospital equipment
Sub-Industry
Health Care Distributors
Sector
Medical
Current Symbol
NASDAQ:HSIC
CUSIP
80640710
Employees
21,600
Year Founded
1932

Sales & Book Value

Annual Sales
$12.40 billion
Cash Flow
$6.17 per share
Book Value
$30.60 per share

Profitability

Net Income
$631.23 million
Pretax Margin
6.67%

Debt

Price-To-Earnings

Miscellaneous

Free Float
136,670,000
Market Cap
$11.52 billion
Optionable
Optionable

Company Calendar

Last Earnings
5/03/2022
Today
5/23/2022
Next Earnings (Estimated)
8/02/2022
Fiscal Year End
12/31/2022

Social Links


MarketRank

Overall MarketRank

2.06 out of 5 stars

Medical Sector

513th out of 1,416 stocks

Medical & Hospital Equipment Industry

3rd out of 3 stocks

Analyst Opinion: 2.3Community Rank: 3.5Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 1.3 5 -4 -3 -2 -1 -













Henry Schein (NASDAQ:HSIC) Frequently Asked Questions

Is Henry Schein a buy right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Henry Schein in the last year. There are currently 1 sell rating, 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Henry Schein stock.
View analyst ratings for Henry Schein
or view top-rated stocks.

When is Henry Schein's next earnings date?

Henry Schein is scheduled to release its next quarterly earnings announcement on Tuesday, August 2nd 2022.
View our earnings forecast for Henry Schein
.

How were Henry Schein's earnings last quarter?

Henry Schein, Inc. (NASDAQ:HSIC) posted its quarterly earnings data on Tuesday, May, 3rd. The company reported $1.30 earnings per share for the quarter, topping analysts' consensus estimates of $1.21 by $0.09. The business had revenue of $3.18 billion for the quarter, compared to the consensus estimate of $3.12 billion. Henry Schein had a net margin of 5.11% and a trailing twelve-month return on equity of 15.70%. Henry Schein's revenue was up 8.7% on a year-over-year basis. During the same period in the prior year, the business earned $1.24 EPS.
View Henry Schein's earnings history
.

When did Henry Schein's stock split? How did Henry Schein's stock split work?

Shares of Henry Schein split on Friday, September 15th 2017. The 2-1 split was announced on Wednesday, August 16th 2017. The newly created shares were payable to shareholders after the market closes on Thursday, September 14th 2017. An investor that had 100 shares of Henry Schein stock prior to the split would have 200 shares after the split.

How will Henry Schein's stock buyback program work?

Henry Schein declared that its board has approved a stock buyback plan on Thursday, May 13th 2021, which authorizes the company to buyback $400,000,000.00 in shares, according to EventVestor. This buyback authorization authorizes the company to purchase up to 3.6% of its stock through open market purchases. Stock buyback plans are often a sign that the company's leadership believes its stock is undervalued.

What guidance has Henry Schein issued on next quarter's earnings?

Henry Schein updated its FY 2022 earnings guidance on Monday, May, 9th. The company provided EPS guidance of $4.75-$4.91 for the period, compared to the consensus earnings per share estimate of $4.86. The company issued revenue guidance of $13.02 billion-$13.39 billion, compared to the consensus revenue estimate of $13.14 billion.

What price target have analysts set for HSIC?

6 analysts have issued 12-month price targets for Henry Schein's stock. Their forecasts range from $72.00 to $103.00. On average, they expect Henry Schein's share price to reach $94.40 in the next year. This suggests a possible upside of 13.1% from the stock's current price.
View analysts' price targets for Henry Schein
or view top-rated stocks among Wall Street analysts.

Who are Henry Schein's key executives?
Henry Schein's management team includes the following people:
What is Stanley M. Bergman's approval rating as Henry Schein's CEO?

451 employees have rated Henry Schein CEO Stanley M. Bergman on Glassdoor.com. Stanley M. Bergman has an approval rating of 94% among Henry Schein's employees. This puts Stanley M. Bergman in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Henry Schein's key competitors?
What other stocks do shareholders of Henry Schein own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Henry Schein investors own include Alibaba Group (BABA), Pfizer (PFE), AbbVie (ABBV), Advanced Micro Devices (AMD), Intel (INTC), NVIDIA (NVDA), QUALCOMM (QCOM), CVS Health (CVS), Micron Technology (MU) and AT&T (T).

What is Henry Schein's stock symbol?

Henry Schein trades on the NASDAQ under the ticker symbol "HSIC."

Who are Henry Schein's major shareholders?

Henry Schein's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.11%), BlackRock Inc. (9.13%), State Street Corp (5.06%), Invesco Ltd. (2.95%), American Century Companies Inc. (2.62%) and Pendal Group Ltd (2.25%). Company insiders that own Henry Schein stock include Deborah Derby, Gerald A Benjamin, James P Breslawski, Kurt P Kuehn, Mark E Mlotek, Michael S Ettinger, Scott Philip Serota, Stanley M Bergman, Steven Paladino and Walter Siegel.
View institutional ownership trends for Henry Schein
.

Which institutional investors are selling Henry Schein stock?

HSIC stock was sold by a variety of institutional investors in the last quarter, including Lazard Asset Management LLC, Invesco Ltd., Woodline Partners LP, Sprucegrove Investment Management Ltd., Sei Investments Co., Ardevora Asset Management LLP, Renaissance Technologies LLC, and Qube Research & Technologies Ltd. Company insiders that have sold Henry Schein company stock in the last year include Mark E Mlotek, Michael S Ettinger, Stanley M Bergman, and Walter Siegel.
View insider buying and selling activity for Henry Schein
or view top insider-selling stocks.

Which institutional investors are buying Henry Schein stock?

HSIC stock was acquired by a variety of institutional investors in the last quarter, including Pendal Group Ltd, American Century Companies Inc., Pzena Investment Management LLC, BlackRock Inc., APG Asset Management N.V., Vanguard Group Inc., Skandinaviska Enskilda Banken AB publ , and Boston Trust Walden Corp. Company insiders that have bought Henry Schein stock in the last two years include Deborah Derby, and Scott Philip Serota.
View insider buying and selling activity for Henry Schein
or or view top insider-buying stocks.

How do I buy shares of Henry Schein?

Shares of HSIC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Henry Schein's stock price today?

One share of HSIC stock can currently be purchased for approximately $83.45.

How much money does Henry Schein make?

Henry Schein has a market capitalization of $11.52 billion and generates $12.40 billion in revenue each year. The company earns $631.23 million in net income (profit) each year or $4.599990 on an earnings per share basis.

How many employees does Henry Schein have?

Henry Schein employs 21,600 workers across the globe.

Does Henry Schein have any subsidiaries?

The following companies are subsidiares of Henry Schein: ACE Surgical Supply Co., ADS Florida, AUV Veterinary Services, Accord, Alpha Scientific, Arcade Dentaire, Arseus, Arseus Dental Solutions, Arseus Lab, Becker-Parkin Dental Supply, BioHorizons Inc., Butler Schein Animal Health, C&M Vetlink, Camlog USA Inc., DNA Anthos Impianti, Dental Cremer, Dental Trey, Elite Computer Italia, Exan Enterprises Inc., General Injectables & Vaccines Inc., HS Brand Management Inc., HS TM Holdings LLC, Handpiece Parts & Repairs Inc., Henry Schein Europe Inc., Henry Schein Latin America Pacific Rim Inc., Henry Schein Medical Systems Inc., Henry Schein Practice Solutions Inc., Jorgen Kruuse, Lincoln Dental Supply, Logiciel Julie, Maddox Practice Group, Maravet, Marrodent, Medivet, Medka, Minerva Dental Limited, Modern Laboratory Services, NLS Animal Health, Noviko, Ortho Organizers, Ortho Technology, Project Helium Holdings LLC, Project Spartan Holdings Corp., RxWorks, SG Healthcare Corp, Sirona Direct, SmartPak Equine LLC, Software of Excellence, Sogim Grimouille, Southern Anesthesia & Surgical, The Exan Group, Veterinary Instrumentation, Vetstreet, W. & J. Dunlop, and scil animal care.

When was Henry Schein founded?

Henry Schein was founded in 1932.

What is Henry Schein's official website?

The official website for Henry Schein is www.henryschein.com.

How can I contact Henry Schein?

Henry Schein's mailing address is 135 DURYEA RD, MELVILLE NY, 11747. The company can be reached via phone at (631) 843-5500, via email at [email protected], or via fax at 631-843-5541.

This page was last updated on 5/23/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.